What's Happening?
Sling Therapeutics, an Ann Arbor, Michigan-based company, has successfully closed a $123 million Series C funding round. This significant investment, led by Forbion, is earmarked to finance a pivotal Phase 3 clinical trial for its oral IGF-1R inhibitor,
linsitinib, which is being developed to treat thyroid eye disease (TED). The company has already commenced dosing patients in the ORBIT trial, which is designed to compare a 150 mg twice-daily dose of linsitinib against a placebo over a 24-week period, enrolling approximately 130 participants. Linsitinib previously met its primary endpoint in the Phase 2b/3 LIDS trial, demonstrating a reduction in proptosis in patients with moderate-to-severe TED, and has received a fast-track designation from the FDA. This development positions Sling Therapeutics ahead of competitors in the oral IGF-1R inhibitor category for TED.
Why It's Important?
This substantial funding and the progression of linsitinib into Phase 3 trials are critical for the treatment landscape of thyroid eye disease (TED) in the U.S. TED is a rare autoimmune disorder characterized by inflammation of the muscles and fatty tissues behind the eye, leading to proptosis, or bulging eyes. Current intravenous IGF-1R inhibitor therapies, such as Amgen's Tepezza (tezepelumab) and Viridian Therapeutics' Lumvoa (veligrotug), are effective but require hospital visits for administration. An oral alternative like linsitinib could significantly improve patient convenience and accessibility to treatment, potentially reducing the burden on healthcare facilities and enhancing the quality of life for TED patients. The fast-track designation from the FDA underscores the urgent need for new treatment options and the potential impact of linsitinib on patient care. Success in this trial could establish a new standard of care, offering a more patient-friendly option for managing this debilitating condition.
What's Next?
Sling Therapeutics will continue to enroll and monitor patients in its pivotal ORBIT trial for linsitinib. The trial's progress and eventual results will be closely watched by the medical community, patients, and investors. If the Phase 3 trial successfully replicates the positive outcomes seen in earlier stages, Sling Therapeutics will likely proceed with submitting a New Drug Application (NDA) to the FDA for approval. The company's closest rival in the oral IGF-1R inhibitor for TED category, Khartis Therapeutics, is expected to begin clinical testing for its early-stage candidate next year, indicating a growing competitive landscape. The outcome of Sling's trial will not only determine the future of linsitinib but also influence the development strategies of other companies in this therapeutic area, potentially accelerating the availability of more diverse treatment options for TED patients.
Beyond the Headlines
The shift towards oral therapies for conditions traditionally treated with intravenous medications represents a broader trend in pharmaceutical development aimed at improving patient autonomy and reducing healthcare costs. For TED patients, an oral treatment could mean fewer disruptions to daily life, greater independence, and potentially better adherence to treatment regimens. This development also highlights the increasing focus on rare diseases, where unmet medical needs are often significant. The success of companies like Sling Therapeutics in securing substantial funding for such specialized treatments demonstrates investor confidence in targeted therapies for niche markets. Furthermore, the competition in the oral IGF-1R inhibitor space suggests a healthy drive for innovation, which ultimately benefits patients by fostering the development of more effective and convenient treatment modalities. This could set a precedent for how other autoimmune and rare diseases are approached in terms of drug development and patient care.
